Adverse reactions and treatment methods of vanzacato/tizacaftor/deuterated ivacaftor composite tablets

Vanzacaftor/tezacaftor/deuterated ivacaftor composite tablets (vanzacaftor, tezacaftor and deutivacaftor) are a new triple drug for the treatment of cystic fibrosis, and its safe medication regimen needs to strictly follow specific specifications. All patients must undergo a comprehensive liver function test before starting treatment, including key markers such as ALT, AST, alkaline phosphatase and bilirubin. Monitoring after medication is equally important. Liver function needs to be reviewed monthly for the first 6 months, then every 3 months for 12 months, and at least once a year thereafter. In terms of administration method, the drug must be taken with fatty food to promote absorption. Children aged 6 to under 12 years old and weighing less than 40kg should be taken orally once a day pan>3 tablets, while patients of the same age group weighing ≥40kg and 12 years old or above are required to take 2 tablets once a day. If the missed dose is within 6 hours, the dose should be taken promptly. If it exceeds 6 hours, the dose should be skipped. Special attention should be paid to the fact that this drug is contraindicated in patients with severe hepatic impairment, and patients with moderate hepatic impairment also need to carefully evaluate the risk-benefit ratio before considering its use.

Vanzacato/Tizacaftor/Deuterated ivacaftor compound tabletsPossible adverse reactions involve multiple systems and require different response strategies. The most common side effects include respiratory symptoms such as cough, sore throat, nasopharyngitis, etc., as well as systemic reactions such as fatigue, flu-like symptoms, and upper respiratory tract infections. These symptoms are usually mild and can be alleviated by symptomatic treatment, and generally do not require interruption of medication. Reactions such as rash and itching may occur in the skin system, which can be observed in mild cases. In severe cases, dose reduction or treatment suspension may be considered. Neurological symptoms such as headaches and sinus congestion are also common and resolve spontaneously in most cases. However, what is more concerning is the potential for serious adverse reactions, especially liver toxicity. If patients develop symptoms of liver injury such as right upper quadrant pain, nausea and vomiting, darker urine, jaundice of the skin or sclera, etc., they should stop taking the drug immediately and seek medical treatment. Also requiring emergency treatment are allergic reactions, which can manifest as rash, urticaria, difficulty breathing, chest tightness and other symptoms, and severe cases can be life-threatening.

Special attention also needs to be paid to the safety of medication for special groups of people. Children and adolescents under 18 years of age may develop lens opacification or cataracts when using this medicine, so eye exams are recommended before and regularly during treatment. Currently, the drug is effective for 6Safety and effectiveness have not been established in children under 10 years of age, so use in this age group is not recommended. In terms of drug interactions, there may be significant interactions between vanzacato/tizakato/deuterated ivacaftor composite tablets and CYP3A system drugs, which may affect efficacy or increase the risk of adverse reactions. Therefore, special caution is required for combined use of drugs. Overall, although It brings new treatment hope to patients with cystic fibrosis, but the management of adverse reactions requires close cooperation between doctors and patients. Only through standardized medication regimens, strict monitoring plans and timely intervention measures can the safety and effectiveness of treatment be ensured. Patients should maintain good communication with their doctors during medication, report any abnormal symptoms in a timely manner, and jointly develop an individualized treatment plan.

Reference link:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/218730s000lbl.pdf